Navigation Links
NeurogesX Reports First Quarter 2009 Results
Date:5/7/2009

$478 $370 Accrued compensation 601 1,039 Accrued research and development 623 1,067 Other accrued expenses 621 540 Notes payable - current portion 1,982 2,833 ------- ------- Total current liabilities 4,305 5,849 Non-current liabilities: Notes payable - non-current portion -- 191 Deferred rent 367 276 ------- ------- Total non-current liabilities 367 467 Commitments and contingencies Stockholders' equity: Common stock 18 18 Additional paid-in capital 209,877 209,370 Deferred stock-based compensation (1) (2) Accumulated other comprehensive income 9 32 Deficit accumulated during the development stage (194,746) (190,144) -------- -------- Total stockholders' equity 15,157 19,274 ------- ------- Total liabilities and stockholders' equity $19,829 $25,590 ======= ======= (1) The balance sheet at December 31, 2008, has been derived from the audited consolidated financial statements at that date. NeurogesX, Inc. Stephen Ghiglieri Chief Financial Officer (650) 358-3310 The Ruth Group Sara Ephraim (investors) (646)
'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
2. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
3. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
4. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
5. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
6. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. NeurogesX Reports Third Quarter 2008 Results
8. NeurogesX to Report Third Quarter 2008 Financial Results
9. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
10. NeurogesX Responds to EMEAs Day 120 Questions
11. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) ... Sensors Market - Growth, Trends & Forecasts (2014-2020)" ... Mexico Biomedical Sensors market is estimated at $0.20 billion ... period 2014-2020 The near future will bring ... of each individual. These sensors can be set to ...
(Date:8/31/2015)... 2015  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... review period following the filing of the Company,s ... the U.S. Food and Drug Administration (FDA) has ... Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... 31, 2015 Trimb Healthcare AB ("Trimb") today ... YouMedical Group BV ("YouMedical"), a Dutch OTC company with ... sales of approximately EUR 16 million, with solid growth ... "Our ambition is to build a leading international OTC ... that goal. YouMedical gives us a stronger North European ...
(Date:8/30/2015)... CHERTSEY , England , August ... Kampagne beendet die 51-jährige Wartezeit   einer Frau   ... und Frauen im Alter von 7-90   ... Programm soll 1200 Frauen behandeln und ...     , Astellas gab heute ...
Breaking Biology Technology:Mexico Biomedical Sensors Market Report 2015-2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 2Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 3Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 4Über 550 Frauen, deren Leben durch "Action on Fistula" transformiert wurde 5
... This release is available in German . When ... light particles, so-called photons, carry sufficient energy, the electrons can be ... was explained by Einstein more than hundred years ago. Until now, ... the atom immediately after the impact of the photon. This point ...
... ... case study that provides a sustainable solution for odor and pathogen ... of beneficial microbial applications. These results are intended to address the ... who recently agreed to identify and investigate thousands of factory farms ...
... ... in Latin America regarding approvals of Stemedica’s allogeneic adult stem cell products for use in ... , ... 24, 2010 -- Stemedica Cell Technologies, Inc., a leader in allogeneic adult stem ...
Cached Biology Technology:Delayed time zero in photoemission 2Delayed time zero in photoemission 3Effective Odor and Pathogen Control in Livestock Operations Revealed in New Case Study 2Stemedica Announces the Appointment of Dr. Csar Amescua Garcia as Medical and Regulatory Affairs Director – Latin America 2
(Date:8/12/2015)... Florida , August 12, 2015 ... pace of mobile payment innovation and advanced biometrics technology ... replace the way consumers rely on using their credit ... with reinventing the future for payment services led by ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ...
(Date:8/10/2015)... , August 10, 2015 ... Eye Tracking Technology for more than two decades, announces ... for integration into all consumer display formats. The SMI ... integration of eye tracking into consumer tablets, laptops, desktop ... smart glasses. Omnivision,s leading sensor technology contributes to the ...
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
Breaking Biology News(10 mins):Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Synaptics Chosen for Human Interface Co-Development on Windows 10 2
... of continental drift provides a good model for understanding terrestrial ... successfully shed light on processes up to 3 billion years ... the earth and crust formation before that point and through ... ago. This is the conclusion of Tomas Naraa of the ...
... tissue using cells derived from the amniotic fluid is ... UCL Institute of Child Health. The paper ... cells derived from the fluids which surround the fetus ... The treatment resulted in longer survival in mice affected ...
... Inc., a Los Angeles based investment banking company, today ... Alliqua, Inc.  During the term of the engagement, WestPark ... and finance, private and public equity and debt financing, ... provide introductions to investors. About Alliqua, ...
Cached Biology News:New understanding of terrestrial formation has significant and far reaching future implications 2Potential new approach to regenerating skeletal muscle tissue 2WestPark Capital, Inc. Engaged By Alliqua, Inc. 2